Ranibizumab: treatment in patients with neovascular age-related macular degeneration.

@article{Pieramici2006RanibizumabTI,
  title={Ranibizumab: treatment in patients with neovascular age-related macular degeneration.},
  author={Dante Joseph Pieramici and Robert L. Avery},
  journal={Expert opinion on biological therapy},
  year={2006},
  volume={6 11},
  pages={1237-45}
}
Vascular endothelial growth factor (VEGF)-A is a major regulator of angiogenesis and vascular permeability implicated in the development of diseases involving pathological angiogenesis and increased vascular permeability, such as neovascular age-related macular degeneration (AMD). LUCENTIS (ranibizumab), a humanized antigen-binding fragment (Fab) that neutralizes all VEGF-A isoforms and their biologically active degradation products, was recently approved by the FDA. Ranibizumab is the first… CONTINUE READING